Shared on 23 Aug 25
Fair value Decreased 20%The downward revision in Spero Therapeutics’ consensus price target largely reflects declines in its future P/E multiple and net profit margin, resulting in a lower fair value estimate of $4.00. What's in the News The phase III PIVOT-PO trial of tebipenem HBr, an investigational oral treatment for complicated urinary tract infections (cUTIs), was stopped early due to efficacy, following an Independent Data Monitoring Committee recommendation.
Shared on 23 Apr 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 17 Apr 25
AnalystConsensusTarget has decreased profit margin from 19.3% to 17.3% and increased future PE multiple from 59.8x to 66.6x.
Shared on 09 Apr 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 02 Apr 25
Fair value Decreased 7.20%AnalystConsensusTarget has decreased revenue growth from -8.8% to -12.2%, increased profit margin from 10.5% to 19.3% and decreased future PE multiple from 102.9x to 59.5x.